U.S.A.'s interesting latest

ORDER TODAY Women's Heart Health Publications Take Care of the Ones You Love Learn more about what you can do to take care of your cardiovascular health and order this set of FREE publications containing information on: • Heart Health for Women  • Women in Clinical Trials Fact Sheet • Menopause & Hormones: Questions to Ask Your Doctor Card • Smoking: Medicines to Help You Quit • Sodium in Your Diet Click here to order now Also Available in Spanish

This message was sent to politikimx@yahoo.gr from: US Government Publishing Office | pueblo@gpo.gov | GPO | 31451 United Ave | Pueblo, CO 81001 myRA is Phasing Out The U.S. Department of the Treasury has decided to discontinue the myRA retirement savings program, and will no longer be accepting new enrollments. Current accounts can remain open until further notice. Keep in mind, your myRA cannot be transferred or rolled over into your employer-sponsored retirement plan or a traditional IRA.  Get answers to important questions about your account, including how to transfer your myRA to another Roth IRA provider, at myRA.gov. How to Talk to Your Kids About Tragic News Tragic stories are reported by news outlets every day. Although you may try to avoid having your children see upsetting news reports about violence or natural disasters, you can't always be successful —especially if your family is impacted directly. Use these resources to help make a difficult conversation easier: This talking points PDF from SAMHSA can help you explain things to your child. Learn how children perceive the news and how to talk to them about what they see with these tips from KidsHealth. Disabled children may be more severely impacted in some cases. The CDC has talking points to help you have that conversation.   MedWatch - The FDA Safety Information and Adverse Event Reporting Program Infant Sleep Positioners: FDA Warning - Risk of Suffocation AUDIENCE: Consumer, Pediatrics ISSUE: FDA is reminding parents and caregivers not to put babies in sleep positioners. These products—sometimes also called “nests” or “anti-roll” products—can cause suffocation (a struggle to breathe) that can lead to death. In the last 13 years, the federal government has received 12 reports of babies known to have died from suffocation associated with their sleep positioners. Most of the babies suffocated after rolling from the side to the stomach. In addition to the deaths, the commission has received dozens of reports of babies who were placed on their back or side in the positioners only to be found later in hazardous positions within or next to the product. To reduce the risk of sleep-related infant deaths, including accidental suffocation and Sudden Infant Death Syndrome (SIDS), the American Academy of Pediatrics recommends that infants sleep on their backs, positioned on a firm, empty surface. This surface should not contain soft objects, toys, pillows, or loose bedding. BACKGROUND: The most common types of sleep positioners feature bolsters attached to each side of a thin mat and wedges to elevate the baby’s head. The sleep positioners are intended to keep a baby in a desired position while sleeping. They are often used with infants under 6 months old. RECOMMENDATION: Parents and other caregivers should not put babies in sleep positioning products. NEVER use infant sleep positioners. Using this type of product to hold an infant on his or her side or back is dangerous. NEVER put pillows, blankets, loose sheets, comforters, or quilts under a baby or in a crib. These products also can be dangerous. Babies don’t need pillows and adequate clothing—instead of blankets—can keep them warm. ALWAYS keep cribs and sleeping areas bare. That means you should also never put soft objects or toys in sleeping areas. ALWAYS place a baby on his or her back at night and during nap time. An easy way to remember this is to follow the ABCs of safe sleep: “Alone on the Back in a bare Crib.” FTC to Conduct Workshop on November 8, Examining Competition Issues Related to Prescription Drug Markets The Federal Trade Commission will hold a workshop on November 8, 2017 entitled, “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics.” Acting FTC Chairman Maureen K. Ohlhausen and U.S. Food and Drug Commissioner Dr. Scott Gottlieb will give the keynote addresses. The Hatch-Waxman Act, passed by Congress more than 30 years ago, provides a regulatory and judicial framework to expedite generic entry into U.S. prescription drug markets. For many drugs, the Act has succeeded in lowering patent-related barriers to generic drug entry, thereby spurring additional competition that has led to lower drug prices. In 2010, Congress created a similar framework for biosimilar drug development under the Biologics Price Competition and Innovation Act. “Competition is key to containing prescription drug costs. During the last decade, generic drugs have saved Americans more than $1.67 trillion,” said Acting Chairman Ohlhausen. “In light of concerns about rising drug prices, it's critical we identify barriers that may prevent drugs from entering the market, even after applicable patent protections have expired.” “One of my highest priorities as FDA Commissioner is to increase competition in the market for prescription drugs and facilitate entry of lower-cost alternatives, like generics,” said Dr. Gottlieb. “At the FDA we’re working hard to reduce barriers to generic competition. We’re pleased to be part of the FTC’s important workshop as part of our efforts to identify obstacles to competition and discuss policy steps that can increase the availability of generic drugs for consumers. I am committed to doing all we can under the FDA’s authority to help reduce the burden on consumers, so that no patient is ever priced out of access to a medicine they need to cure a disease or maintain their health.” The first session of the workshop will explore generic drug markets, including considerations that may preclude entry after relevant patents have expired. Panelists will discuss price and non-price factors that may influence entry in these markets. The second session will evaluate intermediaries in the pharmaceutical supply chain, focusing on pharmacy benefit managers (PBMs) and group purchasing organizations (GPOs). Panelists will discuss how the contractual relationships between intermediaries, manufacturers and health plan sponsors ultimately affect the prices consumers pay for prescription drugs. Throughout the day, speakers will discuss means to encourage entry and eliminate competitive impediments in prescription drug markets. The workshop, which is free and open to the public, will be at the FTC’s Constitution Center Auditorium, 400 7th St., SW, Washington, DC. The event begins at 8:30 a.m. and will be webcast live on the FTC’s website. Registration information, an agenda, directions to the FTC Conference Center, and a list of speakers will be available in the near future on the e